Endometrial cancer patients often have iron deficiency anemia before surgery, which can be effectively treated with oral iron supplementation. Anemia and blood transfusions have been previously associated with perioperative infectious diseases. In the present study the investigators will evaluate the impact of perioperative iron supplementation on the incidence of perioperative infections.
Prehabilitation has a multimodal conception based on three fundamental pillars: improvement of the patient's physical condition, nutritional optimization and other measures such as smoking cessation and correction of anemia. As in the case of multimodal rehabilitation protocols, the actions of prehabilitation programs have synergistic effects, that is, small changes that, by themselves, do not have clinical significance but when added up, they produce a significant improvement in the postoperative evolution of patients. Surgical site infections (SSIs) are considered to be the most common nosocomial infections among surgical patients and constitute a heavy and potentially preventable economic burden on health care providers. Although the impact of blood transfusion on the risk of SSI remains controversial, several studies have shown that anemia and transfusion predispose to postoperative bacterial infections. In the present study the investigators seek to evaluate the impact of per os iron prehabilitation on perioperative outcomes of endometrial cancer patients, including need for transfusion and infectious morbidity.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
156
Ferrous Gluconate 300 MG twice a day
First department of Obstetrics and Gynecology
Athens, Greece
Number of participants with surgical site infection
Participants will be followed-up to determine the incidence of postoperative surgical site infection
Time frame: Postoperatively (up to 30 days)
Required blood transfusions per participant and aggregated mean differences
The number of perioperative (intraoperative and postoperative) blood transfusions per patient will be monitored and compared among the two groups.
Time frame: Perioperatively (up to 10 days)
Number of participants with other postoperative infections
Participants will be followed-up to determine the incidence of other postoperative infectious morbidity (other than surgical site infection)
Time frame: Postoperatively (up to 30 days)
Duration of hospitalization per participant
The duration of hospitalization per participant will be monitored.
Time frame: Postoperatively (until patient exit) up to 30 days
Onset of adjuvant treatment per participant
The interval between surgery and adjuvant treatment will be monitored.
Time frame: Postoperatively up to 24 weeks
Survival rates of included participants
Patients will be screened for recurrence of disease and their survival status will be screened at 3 years
Time frame: Postoperatively (at 3 years postoperatively)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.